Academic Appointments

Honors & Awards

  • 3UL1TR001085-04S1, National Center for Advancing Translational Sciences, National Institutes of Health (2016-2018)
  • Bugher Foundation Postdoctoral Fellowship, American Heart Association (2008-2011)

Professional Education

  • Stroke Research Fellow, RNA aptamers and Regulatable Anticoagulation, Duke University (2012)
  • Fellow, Duke Clinical Research Training Program, Duke University (2011)
  • Postdoctoral Fellow, Heart & Vascular Institute, Penn State College of Medicine, Penn State University (2008)
  • PhD, Bioengineering (an interdisciplinary program in the biosciences), Penn State University (2005)

Research & Scholarship

Current Research and Scholarly Interests

My long-term career goal is to establish an independently-funded research program in the setting of a clinical laboratory, with a focus on translation of genomic technologies.
In the near term, I am interested in investigating clinically-meaningful relationships between personal genomic variation, transcriptomic variation, and clinical phenotype; by applying systematic integrative analyses in select cohorts of rare hematological diseases.


All Publications

  • The effect of surface contact activation and temperature on plasma coagulation with an RNA aptamer directed against factor IXa JOURNAL OF THROMBOSIS AND THROMBOLYSIS Krishnan, A., Vogler, E. A., Sullenger, B. A., Becker, R. C. 2013; 35 (1): 48-56


    The anticoagulant properties of a novel RNA aptamer that binds FIXa depend collectively on the intensity of surface contact activation of human blood plasma, aptamer concentration, and its binding affinity for FIXa. Accordingly, anticoagulation efficiency of plasma containing any particular aptamer concentration is low when coagulation is strongly activated by hydrophilic surfaces compared to the anticoagulation efficiency in plasma that is weakly activated by hydrophobic surfaces. Anticoagulation efficiency is lower at hypothermic temperatures possibly because aptamer-FIXa binding decreases with decreasing temperatures. Experimental results demonstrating these trends are qualitatively interpreted in the context of a previously established model of anticoagulation efficiency of thrombin-binding DNA aptamers that exhibit anticoagulation properties similar to the FIXa aptamer. In principle, FIXa aptamer anticoagulants should be more efficient and therefore more clinically useful than thrombin-binding aptamers because aptamer binding to FIXa competes only with FX that is at much lower blood concentration than fibrinogen (FI) that competes with thrombin-binding aptamers. Our findings may have translatable relevance in the application of aptamer anticoagulants for clinical conditions in which blood is in direct contact with non-biological surfaces such as those encountered in cardiopulmonary bypass circuits.

    View details for DOI 10.1007/s11239-012-0778-7

    View details for Web of Science ID 000312784500007

    View details for PubMedID 23054460

  • Antithrombotic therapy for ischemic stroke: guidelines translated for the clinician JOURNAL OF THROMBOSIS AND THROMBOLYSIS Krishnan, A., Lopes, R. D., Alexander, J. H., Becker, R. C., Goldstein, L. B. 2010; 29 (3): 368-377


    Acute ischemic stroke is the result of abrupt interruption of focal cerebral blood flow. The majority of ischemic strokes are caused by embolic or thrombotic arterial occlusions. Acute stroke management is complex, in part because of the varying etiologies of stroke and the very brief window of time for reperfusion therapy. Efforts to optimize stroke care have also encountered barriers including low public awareness of stroke symptoms. As initiatives move forward to improve stroke care worldwide, health care providers and institutions are being called onto deliver the most current evidence-based care. Updated versions of three major guidelines were published in 2008 by the American College of Chest Physicians, the American Heart Association, and the European Stroke Organization. This article presents a concise overview of current recommendations for the use of fibrinolytic therapy for acute ischemic stroke and antithrombotic therapy for secondary prevention. Future directions are also reviewed, with particular emphasis on improving therapeutic options early after stroke onset.

    View details for DOI 10.1007/s11239-010-0439-7

    View details for Web of Science ID 000275555100018

    View details for PubMedID 20127273